CYB004

CYB004 is Cybin's proprietary deuterated version of DMT, the classical psychedelic in ayahuasca, chemically modified by replacing hydrogens at metabolically-vulnerable positions with deuterium so it survives longer in the bloodstream. The Phase 2 trial in generalized anxiety disorder (NCT06051721) enrolled 36 patients, completed enrollment in September 2025, and is guided for topline data in Q1 2026 [1][7]. The class comparator is MindMed's MM120 (LSD tartrate), which posted a 7.7-point HAM-A reduction vs. placebo at week 12 in its Phase 2b MAIA trial in GAD, with a 65% response rate and 48% remission rate [4]. If CYB004 approaches those numbers with a substantially shorter clinic session, Cybin has a real Phase 2b path. For Cybin (NYSE: CYBN), a small-cap racing MindMed and Compass Pathways to define the psychedelic anxiety category, that readout is directly commercial.

Novel compound. Never approved for any indication. Phase 2 study CYB004-002 in GAD (NCT06051721), sponsored by Cybin IRL Limited (the Irish subsidiary of Cybin Inc.), enrolled 36 participants with moderate-to-severe GAD (GAD-7 score at or above 10, on concomitant antidepressant or anxiolytic therapy). Enrollment completed September 8, 2025, and Cybin reaffirmed topline data guidance for Q1 2026 in its November 2025 quarterly release [1][7][9]. No public readout has been confirmed as of this writeup. Primary endpoint is change in Hamilton Anxiety Rating Scale (HAM-A) from baseline at six weeks after first dose, with follow-up out to 12 weeks. No FDA breakthrough or fast-track designation has been announced publicly for CYB004 in GAD. Cybin's higher-priority asset, CYB003 (a deuterated psilocin analog for major depressive disorder), received Breakthrough Therapy designation in March 2024 and is now in the PARADIGM Phase 3 program: the APPROACH pivotal study is enrolling with topline expected in 2026, EMBRACE initiated mid-2025, and a long-term extension (EXTEND) is running, with combined enrollment of roughly 550 patients [2][8]. Cash position is meaningful: Cybin ended fiscal Q2 2026 with $83.8M cash, and after a $175M financing the pro forma position was $248M, projected to support operations into 2027 at a Q2 net-loss burn of $33.7M [9]. Cybin has framed the CYB004 study as proof-of-concept, not registrational, so even a positive readout requires a larger controlled trial before FDA discussion becomes serious.

DMT binds and activates the 5-HT2A receptor, a serotonin receptor sitting on the surface of cortical neurons [3]. Activating 5-HT2A triggers downstream signaling that psychedelic researchers believe transiently increases neuroplasticity, the ability of neurons to form new connections. The therapeutic idea: a single dosing session under supervision produces a several-hour reset of maladaptive thought patterns that persists for weeks. The target itself is not novel. LSD, psilocybin, and every classical psychedelic act through 5-HT2A, and MindMed's MM120 (LSD tartrate) just validated the 5-HT2A agonist thesis specifically in GAD [4]. What is novel is the compound. Native DMT is degraded within minutes by monoamine oxidase (MAO) enzymes in the gut and liver, which cleave the N-methyl groups on the tryptamine nitrogen. This is why ayahuasca requires an MAO inhibitor and why intravenous DMT trips last only 10 to 15 minutes. Cybin replaced hydrogens with deuterium (an isotope chemically identical but roughly twice as heavy) at metabolically-vulnerable positions of the DMT scaffold. Cybin's public materials describe CYB004 as a deuterated N,N-DMT, and the disclosed patent estate covers deuterated forms of DMT and 5-MeO-DMT, with the deuteration strategy specifically aimed at slowing MAO cleavage of the N-methyl positions [10]. The relevant physical principle is the kinetic isotope effect: the carbon-deuterium bond vibrates more slowly and requires more energy to break than a carbon-hydrogen bond, so enzymes cleave it more slowly. Intended result: more predictable pharmacokinetics and a session on the order of tens of minutes (Cybin's Phase 1 IV data showed roughly 40-minute duration of psychedelic effect) versus psilocybin's 6 to 8 hour session [11]. The CYB004 Phase 2 GAD trial uses intramuscular (IM) administration, not IV. IM DMT has slower absorption, a lower peak concentration, and a longer duration than IV or smoked DMT even without deuteration, so the fair duration comparator for CYB004 is IM DMT, not IV. Target validation for 5-HT2A in anxiety is strong: MM120 hit its primary endpoint in a Phase 2b in GAD in December 2023, and psilocybin depression data supports the class more broadly [4][5].

NCT06051721 (CYB004-002) is a Phase 2, randomized, double-blind, placebo-controlled study of intramuscular CYB004 in adults with moderate-to-severe GAD (GAD-7 at or above 10 at baseline, on stable antidepressant or anxiolytic therapy), with 36 participants enrolled [1][7]. Primary endpoint: change in HAM-A from baseline at six weeks after first dose. HAM-A is a 14-item clinician-administered scale ranging from 0 to 56, where scores of 18 or higher indicate moderate-to-severe anxiety, and a 7-point drop is widely used in the field as a threshold for clinically meaningful response. The small sample size means the study is powered to detect a signal, not to prove definitive efficacy, which is standard for early psychedelic development given the cost of monitored dosing sessions. Follow-up extends to 12 weeks, which allows direct comparison to the MM120 Phase 2b design and read-through on both effect size and durability [4]. The placebo control matters because psychedelics carry very high expectancy effects and functional unblinding is essentially unavoidable, since patients know whether they hallucinated. Cybin has not publicly disclosed an active-placebo strategy (e.g., a subthreshold CYB004 dose intended to blunt unblinding). The randomized dosing structure also generates PK and tolerability data on the deuterated compound in a patient population (not just healthy volunteers as in Phase 1), which is arguably as valuable as the HAM-A number for planning the next study.

Our model estimates a 3% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: 36 patients is thin for a heterogeneous condition like GAD, and a genuine but modest effect could miss statistical significance by chance. Functional unblinding is the class-wide risk: patients who trip know they got drug, patients who do not know they got placebo, and the reported anxiety score gap partly reflects belief in treatment rather than pharmacology. Safety risk: 5-HT2A agonists cause acute cardiovascular effects (transient blood pressure and heart rate spikes during the session) and psychiatric risk if a session goes badly, including acute anxiety, dissociation, and rare persistent perceptual changes. Monitored dosing mitigates but does not eliminate this. Execution risk: Cybin is a small-cap biotech running two parallel psychedelic programs, with CYB003 in MDD as the resource priority. Q2 2026 pro forma cash of roughly $248M against a $33.7M quarterly net loss implies runway into 2027, so near-term cash risk is manageable, but a stumble in the CYB003 PARADIGM Phase 3 (APPROACH topline expected 2026) would compromise the equity story and CYB004's downstream funding regardless of its own data [8][9]. Commercial risk: even with a clean approval, GAD is dominated by generic SSRIs and benzodiazepines. Payers will demand real-world outcomes data before covering a psychedelic that requires clinic dosing at $2,000 to $5,000 per session. The addressable market compresses fast once the filter is patients who fail first-line therapy, can reach a certified clinic, and get reimbursement.

Worth watching, not the marquee Cybin asset. CYB003 in MDD is the pipeline anchor and drives the equity story; CYB004 is the second act. The specific signal to check for in the Q1 2026 topline: HAM-A change from baseline at the six-week primary endpoint, effect size versus placebo, and durability at the 12-week follow-up. The MM120 MAIA benchmark is concrete: -21.9 HAM-A points on 100 µg MM120 versus -14.2 on placebo at week 12 (7.7-point delta, p<0.003, Cohen's d=0.81), with 65% response and 48% remission rates [4]. A CYB004 delta approaching 7 points at 12 weeks matches that benchmark and gives CYB004 a real Phase 2b path. Below 5 points, or a rapid rebound to baseline, and the deuteration strategy has not earned its place next to LSD or psilocybin. The differentiation pitch depends on session duration: Cybin's Phase 1 IV data showed roughly 40-minute effect duration, but the Phase 2 uses IM, and Cybin has not publicly disclosed a firm IM target-session window in humans with GAD, so the 'shorter than psilocybin' claim remains directionally supported but not quantified for the actual clinical context. Check back after Cybin's next quarterly update or a dedicated CYB004 data press release. Also monitor CYB003 PARADIGM APPROACH progress, since a stumble there starves CYB004 of capital regardless of its own data. Broader category watch: if MM120 secures its Phase 3 win and eventual FDA approval in GAD first, CYB004 becomes a fast-follower differentiated on session length rather than mechanism, changing the pricing and payer conversation entirely.